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Drug metabolism by flavin-containing monooxygenases of human and mouse 
1. Introduction 
Flavin-containing monooxygenases (FMOs; EC 1.14.13.8) are present in a wide range 
of organisms, including bacteria, fungi, plants, invertebrates and vertebrates. In 
eukaryotes, the enzymes are located in the membranes of the endoplasmic reticulum 
and catalyze the oxidative metabolism of a broad range of structurally diverse 
chemicals, including therapeutic drugs, dietary-derived compounds and pesticides 
[1,2]. Substrates contain, as the site of oxygenation, a nucleophilic heteroatom, 
typically nitrogen, sulphur, phosphorus or selenium [3]. FMOs are one of the most 
important of the non-cytochrome P450 (CYP) enzymes involved in the phase-1 
metabolism of drugs. Of 860 drugs surveyed, FMOs contribute to the metabolism of 
about 5%, catalyzing about 2% of the more than 4,000 oxidoreduction reactions 
undergone by these drugs [4]. However, as outlined below, this might be an 
underestimate.  
 In this review, we focus on the role of FMOs in the metabolism of drugs in 
human and mouse. We describe the FMO genes and proteins of human and mouse, 
the catalytic mechanism of FMOs and its significance for the metabolism of drugs. 
We outline differences between FMOs and CYPs; discuss factors contributing to 
potential underestimation of the contribution of FMOs to drug metabolism; 
summarise the developmental stage- and tissue-specific expression of FMO genes and 
how this differs between human and mouse; and describe factors that induce or inhibit 
FMOs. We describe the contribution of FMOs of human and mouse to the metabolism 
of drugs in vitro and in vivo and how genetic variation of FMOs affects drug 
metabolism in vitro and in vivo. Finally, we discuss the utility of animal models for 
FMO-mediated drug metabolism in humans.  
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2. FMOs of human and mouse 
Humans possess five functional FMO genes, designated FMO1 to FMO5 [5,6]. FMO1 
to FMO4 are clustered on chromosome 1, in the region q24.3 [6] (Figure 1). The 
cluster contains an additional FMO gene, FMO6P, classified as a pseudogene because 
of its inability to produce a correctly spliced mRNA [7]. FMO5 is located ~26 Mb 
closer to the centromere, at 1q21.1 [6]. A second FMO gene cluster, composed 
entirely of pseudogenes, FMO7P to FMO11P, is present at 1q24.2 [6]. The human 
genome, therefore, contains 11 FMO genes, five of which are functional. In the 
mouse, five Fmo genes, designated Fmo1 to Fmo4 and Fmo6, which are orthologous 
to the corresponding genes of human, are clustered on Chromosome 1 (Figure 1) [6]. 
In mouse, as is the case in humans, the gene encoding FMO5 is located outside the 
main Fmo gene cluster, in this case on mouse Chromosome 3 [6]. A second Fmo gene 
cluster, which contains three genes, designated Fmo9, Fmo12 and Fmo13, is located 
on mouse Chromosome 1, ~3.5 Mb from the main Fmo gene cluster [6]. Fmo6, Fmo9, 
Fmo12 and Fmo13 encode full-length open-reading frames and possess no obvious 
features that would categorize them as pseudogenes. The mouse genome, therefore, 
contains orthologues of the five functional FMO genes of human and four additional, 
potentially functional Fmo genes.   
 
3. Catalytic mechanism 
Much of our knowledge of the catalytic mechanism and substrate preferences of 
FMOs derives from the pioneering work of Dan Ziegler and colleagues (reviewed in 
[8-10]). For catalysis, FMOs require flavin adeninine dinucleotide (FAD) as a 
prosthetic group, NADPH as a cofactor and molecular oxygen as a cosubstrate. The 
catalytic mechanism (Figure 2) is unusual because FMOs activate oxygen, in the form 
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of the C4a hydroperoxide derivative of FAD, in the absence of a bound oxygenatable 
substrate. Steps 1 and 2 are fast and the enzyme is present as the active C4a-
hydroperoxyflavin form, capable of oxygenating any soft nucleophile able to gain 
access to the active site.  
The unusual mechanism of FMOs accounts for their broad substrate range [8-
10].  The rate-limiting step is considered to be either the breakdown of FADH-OH to 
release water or the release of NADP+, both of which occur after the oxygenation of 
substrate and the release of oxygenated product. Consequently, in almost all cases, the 
catalytic constant (kcat) is independent of the structure of the substrate and the 
specificity constant (kcat/KM) is determined largely by the KM for the substrate. 
Because FMOs do not form classical Michaelis-Menten enzyme-substrate complexes, 
KM is a measure of the ease with which a substrate can gain access to the active site. 
Size and shape are important factors that restrict access to the active site [8-11]. 
Charge is also important [8-10]: the best substrates are uncharged or have a single 
positive charge. In contrast, zwitterions or compounds with more than one positive 
charge are excluded, as are compounds with a single negative charge, except in cases 
where the charge is located at an appropriate distance from the site of oxygenation.  
 
4. Differences between FMOs and CYPs 
There are distinct differences in the catalytic mechanisms of FMOs and CYPs. In 
contrast to FMOs, which accept electrons directly from NADPH, CYPs receive 
electrons from NADPH via an accessary protein, NADPH-cytochrome P450 
reductase, and bind and activate oxygen only after binding oxygenatable substrate. 
Whereas FMOs stabilize the active hydroperoxy flavin intermediate, CYPs form a 
relatively unstable ferrous-O2 complex. FMOs have a preference for nucleophilic 
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compounds, whereas CYPs accept less nucleophilic ones. FMOs and CYPs share 
some substrates in common, but often produce different metabolites: although CYPs, 
in common with FMOs, can effect heteroatom oxygenation of nitrogen or sulfur, they 
more often catalyze carbon hydroxylation, heteroatom release (dealkylation) or 
epoxidation [12].  
 CYPs oxidize chemicals via sequential one-electron processes and, thus, are 
more capable of producing reactive, potentially toxic products, some of which can 
inactivate or inhibit CYPs. In contrast, FMOs oxygenate substrates, at a nucleophilic 
heteroatom, via a two-electron mechanism that generally produces polar, readily 
excretable detoxification products. Products of FMO-catalyzed reactions, even those 
that are relatively reactive, do not inhibit the enzyme, but can sometimes inhibit or 
inactivate nearby proteins, including CYPs [13,14]. 
  
5. Factors leading to possible underestimation of the contribution of FMOs to 
drug metabolism 
Methods by which microsomes are prepared and incubated may have lead to 
underestimation of the contribution of FMOs to drug metabolism. In the absence of 
NADPH, FMOs are thermally labile [15]. Consequently, liver perfusion in situ, to 
remove blood before preparation of microsomes, could reduce FMO activity. To 
avoid autooxidative reactions, to which CYPs are prone, microsomes are often 
incubated at 37 oC in the presence of substrate and the reaction initiated by the 
addition of NADPH. Preincubation in the absence of NADPH would diminish FMO 
activity. Optimal FMO activity can be maintained by preparing microsomes at 4 oC, 
adding an NADPH-generating system to the microsomes before preincubation and 
initiating reactions by addition of substrate [15].  
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 To distinguish between the contributions of FMOs and CYPs to the 
metabolism of a drug, incubations can be carried out on microsomes that have been 
pre-heated at 55 oC in the absence of NADPH, which knocks out FMO activity [15]. 
To selectively knock out CYP activities microsomes can be incubated at pH 10, or in 
the presence of carbon monoxide, high concentrations of non-ionic detergents, an 
inhibitory antibody to NADPH CYP reductase, or chemical inhibitors of CYPs [15]. 
However, some CYP inhibitors, such as SKF525A, are substrates for FMO and, 
therefore, could act as an alternative substrate competitive inhibitor of FMO. The 
ability of an FMO to catalyze oxygenation of a particular drug can be confirmed by 
the use of recombinantly expressed FMO. 
 
6. Differences in expression of FMO genes between human and mouse 
There are distinct differences between human and mouse in the tissue-specific 
expression of FMOs and in mouse marked gender-specific differences. In humans, 
expression of the FMO1 gene in liver is switched off at birth [16,17]. This is in 
contrast to mouse, in which FMO1 constitutes a major form of the enzyme present in 
adult liver [18,19]. Silencing of the FMO1 gene in adult human liver may be due to 
the presence, upstream of the hepatic promoter P0, of a LINE-1 element that acts as a 
powerful transcriptional repressor [20]. In extra-hepatic tissues, alternative promoters, 
P1 and P2, are used [6,20]. In adult human, FMO1 is present in kidney, its main site 
of expression [21-23], and in small intestine [22]. In adult mouse, Fmo1 is expressed 
in liver, kidney, lung [19], white adipose tissue [24] and, to a small extent, in whole 
brain, in which it is the most highly expressed FMO [19]. In mouse, expression of 
Fmo1 in liver and lung is greater in females than in males, but in kidney is greater in 
females [19].  
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 In both human and mouse, the main site of expression of FMO2 is lung 
[1,19,25]. FMO2 is also present in kidney [1,19].  
 In humans, expression of FMO3 in liver is switched on after birth [17,21] and 
continues to increase throughout childhood and adolescence, reaching a maximum in 
adulthood [17]. FMO3 declines during menstruation [26] but otherwise there is little 
difference in expression between males and females. In mouse, however, there is a 
profound gender difference in the expression of Fmo3 [19,27]. In females, Fmo3 
expression is switched on after birth, increases to reach a peak at five weeks of age 
and is maintained, albeit at a slightly lower level, throughout adulthood; in males, it 
increases from birth to three weeks of age and is subsequently switched off, being 
undetectable by five weeks of age.  
 The FMO4 gene is expressed in several tissues in human and mouse but, with 
the exception of human pancreas, in all cases the expression is very low [1,6,19]. 
 The gene for FMO5 is expressed in the embryo and in many tissues of fetal 
and adult human and mouse [6]. In both organisms it is most highly expressed in adult 
liver and in this organ its abundance is similar to or greater than that of FMO3 [1,19]. 
In humans, FMO5 is highly expressed also in stomach and pancreas [6] and in the 
small intestine, in which it is the most highly expressed FMO gene [1]. In mouse, it is 
expressed also in kidney [19] and in small and large intestine, where it is the most 
highly expressed isoform [28]. In mouse liver and kidney, Fmo5 expression is higher 
in males than in females [19].  
In mouse liver, mRNAs for FMO1, FMO2, FMO4 and FMO5 are present at 
birth. Those encoding FMO2 and FMO4 exhibit no significant age-related changes. In 
contrast, expression of Fmo1 and Fmo5 changes with age, increasing after birth, to 
reach a peak at five weeks post-partum [19]. As described above, Fmo3 expression 
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exhibits gender-specific age-related changes. With the exception of FMO3 (see 
above), no equivalent information is available on the effect of age on FMO expression 
in humans.  
 
7. Complement of FMOs in major organs involved in drug metabolism 
The complement of FMOs present in major sites of drug metabolism, such as liver, 
kidney, lung and small intestine, differs qualitatively and quantitatively in both human 
and mouse and there are marked species differences [1,19] (Table 1). In adult human 
liver, the main FMOs are FMO3 and FMO5, with FMO1 being absent. FMO3 and 
FMO5 are abundant in female mouse liver, but FMO1 is also present. In adult male 
mouse liver, FMO1 and FMO5 are present, but FMO3 is absent. In human kidney, the 
most abundant FMO is FMO1, followed by FMO2. In female mouse kidney, FMO1 is 
the most abundant isoform, but in male mouse kidney, the abundance of FMO5 is 
similar to that of FMO1. In human lung, by far the most highly expressed FMO 
mRNA is that for FMO2. However, as discussed in Section 12, most humans do not 
produce functional FMO2 from the mRNA. In mouse lung, both FMO1 and FMO2 
are expressed [19,29]. FMO5 is the main isoform present in the small intestine in both 
human and mouse.  
  Interindividual variations have been reported in the abundance in adult human 
kidney of FMO1 (up to 5-fold) [30], and in adult human liver of FMO3 (10- to 20-
fold) [17,31,32] and FMO5 (10-fold) [31]. With the exception of FMO5, FMOs are 
not readily inducible by foreign chemicals (see Section 9). Consequently, individual 
variations in the abundance of FMO1 and FMO3 are likely due to genetic or 
physiological factors, but in the case of FMO5 differential exposure to foreign 
chemicals might contribute.  
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 The presence of FMO1 and FMO5 in fetal human liver [6,23,33] suggests that 
drug substrates for these enzymes that can cross the placenta will be metabolized in 
fetal liver. The amount of FMO1 in adult human kidney [22] is more than that of 
CYPs [34]. Thus, in adult human, FMO1 is likely to contribute substantially to the 
renal metabolism of drugs. The amount of FMO3 in adult human liver [31] is ~ 60% 
of that of CYP3A4 [35], the most abundant hepatic CYP, which catalyzes almost 30% 
of all oxidoreduction reactions undergone by drugs [4]. Given the relative abundance 
of FMO3 in liver and FMO1 in kidney, it is perhaps surprising that only about 2% of 
oxidoreduction reactions undergone by drugs has been attributed to FMOs and 
suggests that their contribution to drug metabolism might be underestimated.    
 
8. Regional-specific expression of FMOs 
In adult female mouse liver, mRNAs encoding FMO2, FMO3 and FMO4 are 
expressed in the periportal region, the expression of FMO3 mRNA being far greater 
than that of FMO2 or FMO4. In contrast, mRNAs encoding FMO1 and FMO5 are 
expressed primarily in the perivenous region, with a gradient across the acini [19]. In 
the kidney, expression of all five FMO mRNAs is localized to the distal and proximal 
tubules and the collecting ducts [19]. FMO1 mRNA was detected also in the 
glomerulous [19]. In lung, FMO1, FMO2 and FMO5 mRNAs are localized to the 
endothelial lining of the alveoli and terminal bronchiole [19]. FMO3 mRNA is 
present only in the terminal bronchiole, and, unlike the situation in liver, in lung this 
isoform is present in both adult male and female mice [19].  
 Little information is available on the regional localization of FMOs in human 
tissues such as liver and kidney. However, in human skin, an organ that is exposed to 
numerous chemicals, FMO1, FMO3, FMO4 and FMO5 mRNAs are localized in the 
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epidermis, sebaceous glands and hair follicles [36]. 
9. Induction and inhibition of FMOs  
In contrast to CYPs, FMOs are not readily inducible by foreign chemicals. An 
exception is FMO5, which is inducible in human hepatocytes by rifampicin [37], in 
HepG2 cells by hyperforin [38] and in a breast cancer cell line by the synthetic 
progestin R5020 [39]. In primary hepatocytes isolated from mice there are gender 
differences in Fmo5 expression in response to some chemicals [40]. In response to 
progesterone, the abundance of FMO5 mRNA was increased in hepatocytes isolated 
from female mice, but reduced in cells isolated from males, and rifampicin induced 
Fmo5 expression to a much greater extent in hepatocytes isolated from female than 
from male mice. In mouse, the abundance of FMO mRNAs can be influenced by diet 
[41].  
 The repression of Fmo3 gene expression in adult male mouse liver can be 
reversed: FMO3 mRNA is induced ~ 6000-fold by 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), but this is not accompanied by a corresponding increase in FMO 
catalytic activity [42]. The response of Fmo3 expression in females to TCDD was 
modest. The increase in the abundance of FMO3 mRNA represents a reversal of the 
repression of Fmo3 expression in the liver of adult male mice rather than an induction 
of gene expression. The results indicate that if mice are the selected species for 
investigation of FMO3 induction, studies should include both male and female 
animals.   
 In contrast to CYPs, FMOs are not readily irreversibly inhibited by foreign 
chemicals. Exceptions are the inhibition of the activity of porcine FMO1 in vitro by 
(N, N-dimethylamino) stilbene carboxylates [43] and of human FMO3 in vitro and in 
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vivo by dietary indoles, present in brassicas [44]. FMOs are, however, subject to 
competitive inhibition by alternative substrates. One such competitive inhibitor, 
methimazole, has been used to distinguish FMO- from CYP-mediated metabolism of 
drugs. However, this approach is problematic because the product of FMO-mediated 
S-oxygenation of methimazole, a sulfenic acid, results in a decrease in CYP content 
[13].   
10. Drug substrates of FMOs 
Of the FMOs, FMO1 has the broadest substrate range, followed by FMO3. FMO1 and 
FMO3 share some substrates in common, e.g., benzydamine, itopride, N-deacetyl 
ketoconazole, voriconazole and tamoxifen, but are relatively selective towards others, 
e.g., FMO1 for chlorpromazine, imipramine and quazepan, FMO3 for procainamide. 
FMO2 and FMO5 have a more restricted range of substrates. In comparison with 
other FMOs, FMO4 is extended at its C-terminus by 23 to 26 amino-acid residues 
[5,45]. Expression of full-length FMO4 has proved problematic. Consequently, 
almost nothing is known of its substrate range and, as FMO4 is expressed in very low 
amounts, it is thought not to play a significant role in drug metabolism.  
 Therapeutic drugs that are substrates for human FMO1, FMO2, FMO3 and 
FMO5 are listed in Tables 2, 3, 4 and 5, respectively. Most drug substrates of FMOs 
are tertiary amines, which are N-oxygenated to form the N-oxide, or sulfides, which 
are S-oxygenated to the sulfoxide. Others include primary amines, such as 
amphetamine [46], which are converted to an N-hydroxylamine, then, via a second 
oxygenation and loss of water, to an oxime; secondary amines, such as N-deacetyl 
ketoconazole [47], which are converted initially to an N-hydroxyamine, then, via a 
second oxygenation, to a nitrone; and thiocarbamides, such as ethionamide [29], 
which are converted to a sulfoxide. N-oxides and sulfoxides are polar and readily 
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excreted and, thus, FMO-mediated metabolism of tertiary amines and sulfides 
represents a detoxification. In contrast, some of the N-hydroxylated products of FMO-
mediated metabolism of primary and secondary amines can inhibit CYPs and, in some 
cases, e.g., the hydroxylated product of N-deacetyl ketoconazole, have toxic effects 
[48].  
FMOs can be stereoselective in the production of product. Examples include 
nicotine [49], pargyline [5], amphetamine [50], sulindac sulfide [30] and cimetidine 
[51]. In some cases, the stereoselectivity of FMOs differs. In the case of pargyline N-
oxygenation, human FMO1 produces only the (+)-enantiomer, whereas human FMO3 
produces predominantly the (-)-enantiomer [5]. For cimetidine S-oxygenation, human 
FMO1 produces more (-)- than (+)-enantiomer, but for human FMO3 the opposite is 
the case [51]. Rettie et al. showed that prochiral sulfoxidation of the non-drug 
substrate methyl p-tolyl sulfide was stereoselective for FMO1, which produces 
exclusively the (R)-sulfoxide, whereas FMO3 produces equal amounts of both the 
(R)- and (S)-sulfoxides [52]. Thus, this compound can be used to distinguish the 
activities of FMO1 and FMO3 in preparations of microsomes in which both of these 
enzymes are present [52]. 
 FMO5 displays no or poor reactivity towards classical FMO substrates and, 
consequently, was thought not to play a significant role in drug metabolism. FMO5 is 
known to catalyze the N- or S-oxygenation of only a small number of drugs in vitro 
(Table 5). A comparison of mouse FMO1, FMO3 and FMO5 catalytic activity 
towards a range of substrates identified unique properties of FMO5 [53]. Recently, 
human FMO5 has been identified as a Baeyer-Villiger monooxygenase [54] able to 
catalyze oxidation of a wide range of carbonyl compounds, via insertion of an oxygen 
atom into a carbon-carbon bond adjacent to the carbonyl group (aldehyde or ketone), 
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to form an ester. Drugs that have been identified as being metabolized by FMO5-
mediated Baeyer-Villiger oxidation include the anticancer compound E7016 [55] and 
the antibacterial MRX-1 [56]. Now that FMO5 has been shown to catalyze a Baeyer-
Villiger reaction, more substrates for this enzyme are likely to be identified. Earlier 
work showed that porcine FMO1 is able to catalyze the Baeyer-Villiger oxidation of 
several carbonyl compounds [57]. However, it is not known whether human or mouse 
FMO1 has this ability.   
 In the majority of cases, drug substrates of FMOs are metabolized also by 
other enzymes, particularly CYPs, and the FMO-catalyzed reaction does not represent 
the major route of metabolism. However, for individuals who possess polymorphic 
variants that decrease catalytic activity of CYPs the contribution of FMOs to drug 
metabolism is likely to be greater. One such example is that of nicotine, which is 
metabolized predominantly by CYP2A6 [58], but also by FMO3 [49]. The oxidation 
of a substrate by CYPs and FMOs usually results in formation of distinct products. 
This is certainly the case for aliphatic tertiary amines, FMOs producing exclusively 
the N-oxide, whereas CYP-mediated oxidation results in N-dealkylation [59]. 
Drugs that are likely to be metabolized exclusively or predominantly by FMOs 
include benzydamine [60], itopride [61], olopatadine [62], pargyline [5], ranitidine 
[31,63] and xanomeline [64], via N-oxygenation, and albendazole [65], cimetidine 
[31,51,66], ethionamide [29] and sulindac sulfide [30], via S-oxygenation.  
Another factor contributing to the potential underestimation of the 
contribution of FMOs to the N-oxygenation of drugs containing tertiary amines is that 
the N-oxides can be retro-reduced to the parent compound by CYPs or other 
reductases [67], such as quinone reductase [68] and aldehyde oxidase [69]. The 
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contribution of FMOs to the metabolism of drugs containing secondary amines may 
also be underestimated. In this case, the initial product of the FMO-catalyzed reaction, 
an N-hydroxyamine, is converted, via a second oxygenation, to a nitrone, which is 
hydrolyzed to produce an aldehyde and a hydroxylated primary amine [70], the latter 
being enzymatically reduced to a primary amine, the same product as would be 
produced from the initial secondary amine substrate by a CYP-mediated N-
dealkylation [71].  
 In addition to drugs, FMOs catalyze the oxygenation of several other foreign 
chemicals, including the pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (FMO1) [72], insecticides, such as phorate and disulfoton (FMO2) [73], and 
dietary-derived compounds, such as trimethylamine (FMO3) [74,75]. However, 
discussion of the involvement of FMOs in the metabolism of non-drug xenobiotics is 
beyond the scope of this review.  
 
11. Role of FMOs in endogenous metabolism 
Because of charge restrictions, discussed in Section 3, almost all small endogenous 
nucleophiles are excluded from the active site of FMOs. Exceptions include the 
biogenic amines tyramine [76] and phenethylamine [77], which are converted by 
human FMO3 to the N-oxide, then via a second, stereoselective, N-oxygenation to the 
trans-oxime. Human FMO3 can also catalyze S-oxygenation of methionine, but, as 
the KM for the reaction is in the mM range, its physiological relevance is questionable. 
Porcine FMO1 can S-oxygenate cysteamine and cysteine S-conjugates, but again, in 
the latter case the KM is high, casting doubt on its metabolic relevance.   
The use of Fmo-knockout mouse lines has revealed that, in addition to 
contributing to the metabolism of drugs, FMO1 and FMO5 have roles in endogenous 
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metabolism, FMO1 as a regulator of energy balance [24] and FMO5 as a regulator of 
metabolic aging, acting via pleiotropic effects, including influencing weight gain and 
plasma concentrations of glucose and cholesterol [78]. 
 
12. Genetic variants of FMOs and their effect on drug metabolism 
 Most humans are homozygous for a nonsense mutation of FMO2, c.1414C>T 
(p.(Gln472*)) [79]. The resultant allele, FMO2*2A, encodes a truncated polypeptide, 
FMO2.2A, that lacks 64 amino-acid residues from its carboxy terminus and is 
catalytically inactive [79]. Thus, in contrast to mouse, most humans do not express 
functional FMO2. The ancestral allele, FMO2*1, which encodes a full-length 
polypeptide, FMO2.1, is present in populations of recent African descent, and in some 
regions of sub-Saharan Africa almost 50% of individuals possess at least one 
FMO2*1 allele [80]. Other deleterious variants have been identified, but these occur 
on the FMO2*2A allele [81]. Individuals who possess an FMO2*1 allele, thus, are 
likely to express a functional protein. The presence of full-length active FMO2 in lung 
microsomes isolated from an FMO2*1 individual has been confirmed [82]. The 
distribution of FMO2*1 and FMO2*2A alleles among world populations has 
implications for interethnic and, in African populations, interindividual variation in 
response to drugs, particularly those for which the lung is a target organ or route of 
entry, such as the antitubercular prodrugs ethionamide and thiacetazone. 
  Rare genetic variants that abolish or severely impair FMO3 activity cause 
primary trimethylaminuria [2,74,83-85]. Affected individuals are unable to 
metabolize dietary-derived trimethylamine, a substrate that is specific for FMO3 [75], 
to its non-odorous N-oxide and, consequently, excrete the smelly free amine in breath, 
sweat and urine [86]. It is expected that sufferers of trimethylaminuria will have 
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impaired ability to metabolize drugs that are substrates for FMO3, and this has been 
shown to be the case for benzydamine [87].  
In addition to rare, loss-of-function variants, at least 15 nonsynonymous 
single-nucleotide polymorphic variants (SNPs) of FMO3 have been identified 
[2,84,88]. A catalogue of genetic variants of FMO3 and their effect on drug 
metabolism [89] can be accessed at the FMO3 locus-specific database 
(http://databases.lovd.nl/shared/genes/FMO3). The effect of many of the SNPs on the 
metabolism of drugs has been tested in vitro. Individually, the most common SNPs, 
c.472G>A(p.(Glu158Lys)) and c.923A>G(p.(Glu308Gly)), have little or no effect on 
enzyme activity [1,2,90,91]. In Europeans and Asians, however, the two SNPs are 
often linked, occurring on the same chromosome [92-95]. The effect of the compound 
variant, (p.(Glu158Lys;Glu308Gly)), on enzyme activity is greater than that of either 
variant alone, and the extent to which it reduces activity depends on the substrate 
[1,2,90,91,94,96,97].  
 The influence of c.769G>A(p.(Val257Met)), a SNP that is common in Asian 
populations, also is substrate dependent. This is illustrated by its effect on the ability 
of FMO3 to catalyze the N-oxygenation of the anti-cancer aurora kinase inhibitors 
danusertib and tozasertib [98]. The variant significantly reduces the N-oxygenation of 
danusertib, but has no effect on production of tozasertib N-oxide. The consequences 
for an individual undergoing treatment with danusertib of possession of a 
c.769G>A(p.(Val257Met)) variant are not known. 
 Three other SNPs affect FMO3 activity: c.183C>A(p.(Asn61Lys)) causes a 
marked reduction in enzyme activity towards four different substrates [99]; 
c.613C>T(p.(Arg205Cys)) has a moderate effect on activity [97]; and 
c.1079T>C(p.(Leu360Pro)) increases activity by 2- to 5-fold [96]. However, each is 
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present at low frequency and/or occurs in a single population group [2] and, 
consequently, has limited significance for the general population.    
 Several SNPs have been identified in the promoter region of FMO3 [100]. 
These segregate into 15 haplotypes. Of these, two markedly decrease transcription in 
vitro, whereas one increases transcription 8-fold [100]. The effect of the promoter-
region SNPs on transcription of the FMO3 gene in vivo is not known.  
 Drug-drug interactions are thought to be rare for substrates of FMO3 [59]. 
However, a study in vitro demonstrated that FMO3-catalyzed N-oxygenation of 
benzydamine was inhibited by several substrates, including itopride, tozatertib, 
methimazole and trimethylamine, and S-oxygenation of sulindac sulfide was inhibited 
by methimazole [101], but, as discussed in Section 9, the use of methimazole as an  
inhibitor of FMO activity can be problematic. It is suggested that individuals with 
reduced FMO3 activity, such as those with the (p.(Glu158Lys;Glu308Gly)) 
compound variant, might experience unexpected consequences in drug response if 
exposed to more than one FMO3 substrate.  
 FMO3 activity might be influenced by factors other than polymorphic 
variation. For instance, in the presence of excess nitric oxide, FMO3 undergoes S-
nitrosylation, which reduces the ability of the enzyme to catalyze ranitidine N-
oxygenation [102], and the availability of the transcription factors HNF-4 and NF-Y 
may influence FMO3 expression [103]. 
Few nonsynonymous SNPs have been identified in FMO1 and each occurs at 
low frequency [2,91,104]. Of those tested, only one had an effect on enzyme activity 
in vitro: c.1504C>T(p.(Arg502*)), which abolished activity towards methimazole, but 
had no effect on activity towards three other substrates [105]. A relatively common 
SNP, g.-9536C>A (the FMO1*6 allele), located in a YY1 element of the fetal liver-
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specific promoter of FMO1, prevented binding of the transcription factor and 
decreased promoter activity in vitro, but did not correlate with lower expression of 
FMO1 in fetal liver in vivo [106].  
Very few nonsynonymous SNPs have been identified in the genes encoding 
FMO4 and FMO5 [2,104]. Of these, most occur at very low frequency and none is 
known to affect enzyme activity [2,104]. 
Although FMO genetic variants, especially those affecting the activity of 
FMO3, are known to influence drug metabolism in vitro, an understanding of the 
impact of FMO variants in vivo is limited to a small number of studies in humans. In 
mouse, studies in vivo using Fmo-knockout lines have provided additional 
information (see Section 13).  
Sulindac sulfoxide is a prodrug converted by gut bacteria to sulindac sulfide, 
the active form of the drug, which is metabolized by FMO3 back to the inactive 
sulfoxide and, then, to sulindac sulfone [30]. The FMO3 variants (p.(Glu158Lys)) and 
(p.(Glu308Gly)) decrease FMO3 activity towards sulindac in vitro [30]. In patients 
with familial adenomatous polyposis undergoing treatment with sulindac, the variants 
are associated with regression of existing polyps and protection against adenoma 
formation, particularly in individuals homozygous for the double variant 
(p.(Glu158Lys;Glu308Gly)) [107,108]. It is thought that reduction of FMO3 activity, 
as a consequence of these polymorphic variants, would result in higher circulating 
concentrations of the active sulindac sulfide.  
Conversion of ranitidine to its N-oxide by FMO3 was demonstrated in vitro 
using human liver microsomes [31]. Subsequently, the double variant 
(p.(Glu158Lys;Glu308Gly)) was found to have a reduced capacity for ranitidine N-
oxygenation [94]. N-oxygenation of ranitidine by FMO3 has been confirmed in vivo 
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[93]; individuals heterozygous or homozygous for the (p.(Glu158Lys;Glu308Gly)) 
double variant excreted lower amounts of ranitidine N-oxide in their urine than did 
individuals homozygous for the ancestral (p.(Glu158;Glu308)) allele [93,94]. 
Although benzydamine is effectively converted in vitro to benzydamine N-
oxide by FMO1 and FMO3 [60], the lack of expression of FMO1 in adult human liver 
enables benzydamine to be used as a probe for FMO3 activity in vivo. The role of 
FMO3 in benzydamine metabolism in vivo was confirmed in a study of patients 
suffering from trimethylaminuria, caused by mutations that severely impair FMO3 
activity, in whom plasma and urinary concentrations of benzydamine N-oxide were 
markedly reduced [87]. 
The antipsychotic olanzapine is converted in vitro to its N-oxide by FMO3 
[109] and, through the action of CYPs, can be hydroxylated or N-demethylated 
[109,110]. The N-oxide can be formed also by CYP2D6 in vitro, but olanzapine 
metabolism in vivo is not influenced by CYP2D6 genotype [111,112]. Olanzapine N-
oxide formation in vitro by the FMO3 variant (p.(Glu158Lys;Glu308Gly)) was lower 
than by the ancestral form, (p.(Glu158;Glu308)) [113]. When the influence of this 
compound variant was examined in vivo the C/D (median dose-adjusted steady-state 
serum concentration) of olanzapine N-oxide in patients homozygous for 
(p.(Glu158Lys;Glu308Gly)) was ~50% lower than in individuals heterozygous or 
homozygous for the ancestral form, but the variant allele had no effect on the plasma 
concentration of olanzapine [114]. In a study of Japanese, several genotypes of FMO3 
and CYPs were found not to be associated with changes in olanzapine clearance, the 
conclusion being that the drug is subject to multi-pathway metabolism and if one 
pathway is less effective others compensate [112]. Variants of FMO1 have been 
shown to alter olanzapine metabolism. In this case, the non-coding variant FMO1*6, 
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which decreases promoter activity in vitro (see above), was found to increase serum 
C/Ds in patients [114].  
Itopride, a gastroprokinetic agent, undergoes N-oxygenation through the action 
of FMO3 in vitro [61] and in vivo [115] and this is considered the major route of 
metabolism. Chinese individuals homozygous for (p.(Glu158Lys;Glu308Gly)) had 
higher plasma concentrations of itopride and lower concentrations of the N-oxide than 
those homozygous for the ancestral form (p.(Glu158;Glu308)) [115].  
The involvement of FMO3 in clozapine N-oxygenation was demonstrated in 
vitro [116]. A study in vivo found no correlation between clozapine N-oxide 
production and the (p.(Glu158Lys)), (p.(Val257Met)) or (p.(Glu308Gly)) variants 
[92]. 
  FMO3 converts nicotine to its N-oxide [49] and, in humans, 4-7% of nicotine 
equivalents are excreted as the N-oxide. CYP2A6, however, is the most important 
contributor to nicotine metabolism and nicotine N-oxide excretion is increased to 
~30% of the absorbed nicotine in individuals homozygous for a CYP2A6 deletion 
[117]. Polymorphisms that influence FMO3 activity would, therefore, be expected to 
be of greater importance in individuals with compromised CYP2A6 activity.  
13. Mouse models for FMO-mediated drug metabolism 
A consequence of the marked differences between human and mouse in expression of 
FMO1 and FMO3 in adult liver and the lack of functional FMO2 in most humans is 
that there are distinct differences between the species in the metabolism of drugs in 
vivo by FMOs. For instance, drug substrates of FMO1 will be metabolized in mouse, 
but not human, liver; substrates of FMO2 will be metabolized in mouse, but not in the 
majority of humans; and substrates for FMO3 will be metabolized in liver of humans 
and female mice, but not of male mice. Therefore, wild-type mouse is not a good 
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animal model for FMO-mediated drug metabolism in humans. However, female mice, 
because they express FMO3 in adult liver, may be useful as a model for FMO3-
mediated metabolism, and, if used in combination with adult male mice, which lack 
hepatic FMO3, for confirming the participation of FMO3 in metabolism of a drug.  
Few studies have directly compared the contribution of FMOs to drug 
metabolism in vivo in humans and mice. A study of procainamide, using a urinary 
metabolite profiling approach, concluded that in humans N-oxidation represents a 
major metabolic route, producing procainamide N-oxide and N-acetyl procainamide 
N-oxide, whereas in mice this was a minor route [118]. Experiments in vitro 
confirmed that both FMO3 and FMO1 catalyze oxygenation of procainamide and N-
acetyl procainamide, the rates of formation being higher for FMO3. However, the 
mouse study used adult males and the differences found between human and mouse 
likely result from the lack of FMO3 in adult male mouse liver.  
Female mice in which the genes for FMO1, FMO2 and FMO4 have been 
knocked out (Fmo1(-/-), Fmo2(-/-), Fmo4(-/-)) [119] express in adult liver FMO3 and 
FMO5, but no other FMOs, and, thus, for most humans, would be a good animal 
model for FMO-mediated drug metabolism. The use of Fmo-knockout mouse lines 
can also help assess the contribution of a FMO protein to the metabolism of a drug 
that undergoes multi-pathway metabolism in vivo [120]. For instance, the 
antidepressant imipramine is oxygenated only by FMO1, to produce the N-oxide 
[119]. Imipramine N-oxide undergoes retroreduction in vivo, thus, quantification of 
the oxygenated product in plasma or urine can miss or underestimate the contribution 
of FMO1 to overall metabolism and clearance of the drug. Using an Fmo1-null mouse 
model, imipramine was shown to cause sedation only in wild-type animals, i.e., those 
that produced imipramine N-oxide in brain [119]. Adverse behavioural changes, such 
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as tremor, were observed only in mice that lacked FMO1 (the knockout mice), which 
produced higher amounts in brain of desipramine, a product of CYP-mediated 
metabolism.  
FMO2 catalyzes the S-oxygenation of the antitubercular prodrugs ethionamide 
and thiacetazone in vitro [29,121]. The triple knockout mouse (Fmo1(-/-), Fmo2(-/-), 
Fmo4(-/-)) was used to better mimic the situation in human, with respect to expression 
of FMOs in lung, and to establish whether a lack of FMO2 influences the metabolism 
of ethionamide in vivo [122]. The plasma concentration of ethionamide was found to 
be higher in knockout than in wild-type mice and that of ethionamide S-oxide to be 
higher in wild-type than in knockout animals, confirming the involvement of FMO2 
in the metabolism of ethionamide. To be effective ethionamide must be taken up by 
mycobacteria in the lungs and subsequently metabolized, by the bacterial 
monooxygenase  EtaA, to the sulfenic acid, which acts as the therapeutic agent [123]. 
Metabolism of ethionamide in the lung by FMO2 to the sulfoxide and, subsequently, 
to a potentially toxic sulfenic acid, would be expected to reduce drug efficacy, by 
diminishing the amount of prodrug available for uptake by mycobacteria, and increase 
harmful side effects.  
14. Conclusions 
Five functional FMOs, FMOs 1-5, are present in humans. The catalytic 
mechanism of FMOs, in which oxygen is activated in the absence of bound substrate, 
is unusual. It enables FMOs to oxygenate any nucleophile able to gain access to the 
active site, thus accounting for their broad substrate range. Human, FMO5 has been 
identified as a Baeyer-Villiger enzyme that can oxygenate a range of electrophilic 
substrates. Baeyer-Villiger oxidations can also be catalyzed by porcine FMO1. 
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Whether this is the case for FMO1 of human or mouse remains to be established.  
FMO-catalyzed reactions are generally detoxifications, producing polar, 
readily excretable metabolites. Most drug substrates of FMOs are metabolized also by 
other enzymes, particularly CYPs, but some are metabolized predominantly or 
exclusively by FMOs. The contribution of FMOs to drug metabolism might be 
underestimated, owing to the use of methods for preparation and incubation of 
microsomes that do not preserve FMO activity. In contrast to CYPs, FMOs are not 
readily induced or inhibited, but genetic variation, particularly of FMO2 and FMO3, 
affects the metabolism of drug substrates of these enzymes.  
 There are marked differences between human and mouse in developmental 
stage- and tissue-specific expression of FMOs. Consequently, human and mouse 
differ in the complement of FMOs present in liver, kidney and lung, the main sites of 
drug metabolism. The species differences are most striking in adult liver: in humans, 
the most abundant FMOs are FMO3 and FMO5, with FMO1 being absent; in mouse 
FMO1, along with FMO5, is present and, in females, but not in males, FMO3 also is 
present. Thus, mouse is not a good animal model for FMO-mediated drug metabolism 
in humans. However, female mice in which the Fmo1, Fmo2 and Fmo4 genes have 
been disrupted (Fmo1(-/-), Fmo2(-/-), Fmo4(-/-)) express in adult liver FMO3 and FMO5, 
but no other FMOs, and, thus, for most humans are a good model for FMO-mediated 
drug metabolism.  
15. Expert opinion 
A number of drugs have been identified as substrates for FMOs, some being 
metabolized predominantly or exclusively by these enzymes. Research on Phase-1 
drug metabolism has concentrated on CYPs, and methods commonly used for the 
 24 
preparation and incubation of microsomes can result in selective loss of FMO activity, 
leading to potential underestimation of the contribution of FMOs to drug metabolism. 
Thus, despite the broad substrate range of FMOs and their relative abundance in liver, 
kidney and lung, the major sites of drug metabolism, the number of drugs identified as 
being metabolized by FMOs is relatively small. The adoption of methods for 
microsome preparation and incubation that favour retention of FMO activity, 
combined with selective ablation of CYP activity, would help achieve a more 
complete appreciation of the contribution of FMOs to drug metabolism. The 
identification of FMO5 as a Baeyer-Villiger monooxygenase indicates that FMO5 has 
a more important role in drug metabolism than hitherto suspected and that additional 
drug substrates of FMO5 are likely to be identified.  
 The substrate preferences and reactions catalyzed by FMO5 differ from those 
of other mammalian FMOs, suggesting that FMO5 may have a distinct mechanism of 
action. It will be important to establish whether this is the case. A detailed 
understanding of the mechanism of action of mammalian FMOs has been hindered by 
the lack of 3D structures of these proteins.  
FMO-catalyzed reactions generally form polar, readily excretable 
detoxification products, whereas CYPs are more able to produce reactive, potentially 
toxic products. In contrast to CYPs, FMOs, with the exception of FMO5, are not 
readily induced or inhibited by foreign chemicals. These differences between FMOs 
and CYPs indicate that drugs that are metabolized predominantly by FMOs would be 
less likely to elicit drug-drug interactions and potentially harmful side effects, and that 
the design of such drugs would offer clinical advantages.  
The human gut microbiome makes important contributions to the metabolism 
of orally administered drugs, for instance, in production of sulindac sulfide, the active 
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form of the prodrug sulindac, which is subsequently inactivated by metabolism by 
FMO3. There are considerable inter- and intra-individual differences in the 
composition of gut flora and the effect of these on drug metabolism is not well 
understood.  
The general lack of induction or inhibition of FMOs indicates that the 
interindividual variation in abundance or activity of FMOs is largely the result of 
genetic or physiological factors. This offers the possibility that genotyping individuals 
for FMO variants would identify those who might experience problems when treated 
with drugs metabolized by FMOs.  
Investigation of FMO-mediated drug metabolism would benefit greatly from 
the availability of an animal model that accurately reflects the metabolic capacity of 
human with respect to FMOs. The functional capabilities in vitro of FMOs of mouse 
are very similar to those of their human orthologues. However, owing to marked 
differences between human and mouse in the abundance of FMOs in the major organs 
of drug metabolism, particularly liver, mouse is not a good model for investigation of 
FMO-mediated metabolism in vivo. This problem can be overcome by the 
development and use of knockout-mouse lines in which selected Fmo genes have 
been disrupted. For instance, female Fmo1(-/-),Fmo2(-/-), Fmo4(-/-) mice express in adult 
liver FMO3 and FMO5, but not FMO1, a complement of FMOs similar to that in the 
liver of Europeans, Asians and most Africans, and, thus, are a good model for most 
humans. Wild-type adult male mice are natural liver-specific knockouts for Fmo3 
and, thus, in conjunction with wild-type females, which do express Fmo3, can be used 
to investigate the role of FMO3 in metabolism of a drug. It is predicted that the use of 
knockout-mouse lines will facilitate advances in understanding the contribution of 
FMOs to the metabolism of therapeutic drugs.   
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The discovery that FMO1 and FMO5 function in endogenous metabolism 
initiates an exciting new area of research and has important implications for drug 
therapy. Drugs that are substrates for these enzymes may compete with endogenous 
substrates and, thus, affect energy homeostasis, in the case of FMO1, or metabolic 
aging, in the case of FMO5, with potential effects on therapeutic response and 
endogenous metabolic functions. Induction of FMO5 by some therapeutics may also 
have adverse effects on the metabolic health of patients.  
 
 
Article highlights box 
 FMOs are involved in the metabolism of a number of therapeutic drugs; in 
most cases the drugs are metabolized also by other enzymes, particularly 
CYPs, but some are metabolized exclusively or predominantly by FMOs 
 The contribution of FMOs to drug metabolism may be underestimated, in 
particular, the ability of FMO1 and FMO5 to catalyze Baeyer-Villiger 
reactions 
 Human and mouse differ with respect to the complement of FMOs present in 
major organs of drug metabolism, consequently, wild-type mouse is not a 
good model for FMO-mediated metabolism in human 
 Genetic variants of FMOs, particularly of FMO2 and FMO3, affect 
metabolism of substrates of these enzymes 
 FMO1 and FMO5 function in endogenous metabolism, which has implications 
for drug therapy 
 Female knockout mice in which the Fmo1, Fmo2 and Fmo4 genes have been 









Figure 1. Chromosomal localization and arrangement of FMO genes of human 
and mouse. Arrows represent direction of transcription. Diagram not to scale.  
 
Figure 2. Catalytic cycle of mammalian FMOs. Evidence for the cycle is based on 
spectrophotometric and kinetic studies (reviewed in [8,10]). NADPH binds and 
reduces the prosthetic group FAD to FADH2 (step 1). Molecular oxygen then binds 
and is reduced, forming C4a-hydroperoxyflavin, which is stabilized by NADP+ (step 
2). Substrate (S) is oxygenated via nucleophilic attack on the distal oxygen of the 
C4a-hydroperoxyflavin, leaving the prosthetic group in the form of C4a-
hydroxyflavin (step 3). Water is then released, reforming FAD (step 4) and the final 
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Table 1.  Major FMO forms expressed in adult human and mouse tissues 
 
 Human Mouse male Mouse female 
Liver FMO3, FMO5 FMO1, FMO5 FMO1, FMO3, 
FMO5 
Lung FMO2 FMO1, FMO2,  FMO1, FMO2 






















Table 2. Drug substrates of human FMO1  
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N-deacetyl ketoconazoleb antifungal N-hydroxylation recombinant 
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Nomifensine antidepressant N-oxygenation recombinant 
protein 
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Pargyline monoamine oxidase 
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Voriconazole antifungal N-oxygenation recombinant 
protein 
[141] 










a metabolite of disulfiram, product is a sulfine; bmajor metabolite of ketoconazole; cmetamphetamine 
hydroxylamine is further converted by FMO action to a mixture of nitrones, which are subsequently 
hydrolysed to yield an aldehyde and a hydroxylated primary amine, the latter then being reduced to a 
primary amine; dactive metabolite of esonarimod; ethe active metabolite of the prodrug sulindac; fmajor 










Table 3. Drug substrates of human FMO2.1 
 
Substrate Type of drug Reaction Analytical 
system 
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Table 4. Drug substrates of human FMO3 
  
Drug Substrate Reaction Analytical 
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Ethionamide antitubercular S-oxygenation recombinant 
protein 
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Nicotine adenosine receptor 
ligand, stimulant 





Nomifensine antidepressant N-oxygenation recombinant 
protein 
[133] 















Pargyline monoamine oxidase 




Phospho-sulindac nonsteroidal anti- S-oxygenation liver [134] 
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an oxime; bmetabolite of disulfiram, product is a sulfine; cmajor metabolite of ketoconazole; 
dmetamphetamine hydroxylamine is further converted by FMO action to a mixture of nitrones, which 
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being reduced to a primary amine; eactive metabolite of esonarimod; fthe active metabolite of the 
prodrug sulindac; gmajor metabolite of tazarotene.  
 
 
Table 5. Drug substrates of human FMO5 
  
Substrate Type Reaction Analytical 
system 
Reference 
















































S-oxygenation purified protein [63] 
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